Wang Y, et al. - In this single-center, retrospective study, the efficacy and safety profiles of sorafenib and apatinib were compared in patients with intermediate- and advanced-stage hepatocellular carcinoma (HCC). On analysis of clinical data of 72 patients, diagnosed with intermediate or advanced HCC from January 2014 to December 2016, researchers identified 38 patients treated with sorafenib [one patient had complete response (CR), 5 patients had partial response (PR), and 10 patients had stable disease (SD)] and 34 patients treated with apatinib (6 patients had PR and 7 patients had SD with no cases of CR). Apatinib was shown to have a promising clinical outcome. However, the sorafenib group demonstrated better clinical efficacy with no significant difference in safety profile.